Comp Set AARTIPHARM AARTIDRUGS× ADVENZYMES× AGARWALEYE× + AKUMS + ALIVUS + APLLTD + CORONA + HCG + JLHL + MARKSANS + METROPOLIS + PARKHOSPS
In ₹ Crore except Per Share
Latest Annual
AARTIPHARM
FY26
AARTIDRUGS
FY26
ADVENZYMES
FY26
AGARWALEYE
FY26
Peer
Average
Valuation — at last close P/E 48.14× 21.02× ◆ 17.52×116.08× 51.54× -7% P/B 3.96× 2.65× ◆ 1.81×7.64× 4.03× -2% EV/EBITDA 24.61× 15.09× ◆ 10.16×27.13× 17.46× +41% Market Cap ₹8,410 Cr ₹4,098 Cr ₹2,956 Cr ₹15,482 Cr ₹7,512 Cr +12% Growth Revenue CAGR 3Y -2.20% -1.89% ◆ 11.32%— 4.71% -147% Revenue CAGR 5Y — 3.55% ◆ 8.24%— 5.89% Net Income CAGR 3Y -3.35% 5.43% ◆ 18.68%— 12.05% -128% Revenue YoY (latest Q) ◆ 45.92%19.01% 2.08% 25.97% 15.69% +193% Net Income YoY (latest Q) ◆ 155.96%-7.12% -4.58% 44.56% 10.95% +1324% Profitability EBITDA Margin 20.29% 12.05% ◆ 30.72%27.38% 23.38% -13% Net Income Margin 9.60% 7.60% ◆ 23.28%8.08% 12.99% -26% Return on Common Equity 8.40% ◆ 13.36%11.05% 6.84% 10.42% -19% Return on Capital Employed 11.05% ◆ 13.34%11.61% 8.79% 11.25% -2% Return on Assets 5.47% 7.23% ◆ 10.03%4.42% 7.23% -24% Credit & Quality Total Debt/Equity 0.32× 0.37× ◆ 0.01×0.07× 0.15× +113% Interest Coverage 5.65× 7.19× ◆ 71.91×3.24× 27.45× -79% Scale — latest FY Revenue / Total Income ₹1,819 Cr ₹2,565 Cr ₹746 Cr ₹2,080 Cr ₹1,797 Cr +1% Net Income ₹175 Cr ₹195 Cr ₹174 Cr ₹168 Cr ₹179 Cr -2% Total Assets ₹3,482 Cr ₹2,815 Cr ₹1,839 Cr ₹3,942 Cr ₹2,865 Cr +22% EPS ₹19.27 ₹21.36 ₹15.08 ₹4.21 ₹13.55 +42% Book Value per Share ₹234.35 ₹169.7 ₹145.81 ₹63.93 ₹126.48 +85%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › » Latest: FY26 · Consolidated CHART » ALPHA AI » COMP » FA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95% .
